米氮平治疗脑卒中后抑郁对照研究的Meta分析

Meta-ananlysis of Comparative Study on Mirtazapine in the Treatment of Post-stroke Depression

目的探讨米氮平治疗脑卒中后抑郁的疗效和不良反应的差异。方法采用Meta分析对9项米氮平与其他抗抑郁剂治疗脑卒中后抑郁对照研究的文献进行再分析,评价其合并效应量大小和综合显著性检验。结果米氮平治疗前后的自身对照,合并效应量d=4.56,95%CI(3.38,5.75),综合显著性检验(χ2=7.54,P<0.01),提示米氮平治疗脑卒中后抑郁前后症状学变化差异有统计学意义,效应极强;米氮平与对照药在第2周末和治疗结束后的组间比较,分别为d=-1.53,95%CI(-2.01,-1.04),χ2=6.19,P<0.01;d=-1.02,95%CI(-1.87,-0.18),χ2=2.38,P<0.05,提示米氮平组疗效好于对照组,且起效快。结论米氮平治疗脑卒中后抑郁的疗效显著。

Objective To study the difference of efficacy of mirtazapine in the treatment of post - stroke depression. Methods 9 comparative studies of mirtazapine and other antidepressants in the treatment of post - stroke depression were ana- lyzed by Meta - ananlysis. Results The significant difference in change of symptom after and before treatment by mirtazapine was found, d = 4. 56, 95% CI （3.38, 5.75 ）, X2 = 7.54, P 〈 0. 01. Comparison between mirtazapine and the controlled anti- depressants at 2 weeks treatment and at the end of each trial showed that d = - 1.53, 95 % CI （ -2. 01, - 1.04） , x2 = 6. 19, P 〈 0. 01 ; d = - 1.02, 95% CI （ - 1.87, - 0. 18）, X2 = 2. 38, P 〈 0. 05. Which revealed that mirtazapine difference from other antidepressants is in side effects. Conclusion Mirtazapine effective than the control drug.